Trenkwalder C, et al. - In this investigation, researchers ascertained if increased fixed doses of 65 or 105 mg of carbidopa (ODM-101/65 and ODM-101/105) combined with 75, 100, 125, or 150 mg of levodopa and 200 mg of entacapone could improve "off" time in fluctuating Parkinson's disease (PD) vs the standard combination of 4:1 levodopa/carbidopa with the usual 200 mg of entacapone (LCE) over a 4-week treatment period. According to this randomized, double-blind, double-dummy, active-controlled, crossover, multicenter, phase 2, proof-of-concept study, increasing the dose of carbidopa combined with levodopa and entacapone may improve daily "off" times in treating fluctuating PD. Using catechol-O-methyltransferase activity to genotype patients with PD can improve individual treatment strategies. While mostly mild or moderate in severity, nausea, dizziness, drug-effect decrease, and dyskinesia were the most common treatment-related adverse effects. Diarrhea, myocardial ischemia and blood creatine kinase increase were treatment-related serious adverse events.